Allosteric EGFR Inhibitor Compounds for Resistant Mutant Selectivity

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for cancer targeting EGFR mutants, particularly T790M/L858R, T790M/L858R/C797S, L858R, and L858R/C797S, lack selective allosteric inhibitors that effectively inhibit these mutations.

Innovation Solution

Development of novel compounds such as 2-(4,7-Dichloro-6-(4-(piperazin-1-yl)phenyl)-2H-indazol-2-yl)-2-((R)-6-fluoro-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-1-yl)-N-(thiazol-2-yl)acetamide and related structures that act as selective allosteric inhibitors of these EGFR mutants.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current EGFR inhibitor treatments are used, then cancer treatment is provided, but selective inhibition of T790M/L858R, T790M/L858R/C797S, L858R, and L858R/C797S mutants is insufficient

Engineering Contradiction:

Improveselective inhibition efficacyVSAvoidmutant coverage specificity

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent applies local quality by designing compounds with specific structural features (indazole core with particular substituent patterns) that confer selective binding affinity to mutant EGFR variants. The molecular structure is optimized to interact with specific mutant configurations (T790M/L858R, T790M/L858R/C797S, etc.) while maintaining differentiated activity profiles across mutant types.

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent employs parameter changes by systematically varying molecular parameters (substituent types, positions, and configurations on the indazole core) to tune the selectivity and potency of EGFR mutant inhibition. Different compound variants are designed with modified parameters to target specific mutant combinations, achieving precise selective inhibition.

Inventive Principle:

Principle #35Parameter changes

2Reliability

If novel allosteric inhibitor compounds are developed, then selective inhibition of EGFR mutants is achieved, but compound complexity increases

Engineering Contradiction:

Improvemutant-selective inhibitionVSAvoidmolecular structure complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent applies segmentation by dividing the molecular structure into distinct functional modules: a core indazole scaffold and various substituent groups (pyrroloimidazole, thiazole, amide, and diverse aromatic substituents). This modular architecture allows systematic optimization of each segment's contribution to selectivity while managing overall molecular complexity.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent employs composite materials principles by combining multiple heterocyclic moieties (indazole, pyrrolo[1,2-c]imidazole, thiazole) with specific substituent patterns to create composite molecular structures. These composite structures achieve enhanced mutant-selective binding properties that individual components cannot provide alone.

Inventive Principle:

Principle #40Composite materials

Data Source

PatentUS12479849B2EGFR inhibitors for the treatment of cancer

Publication Date: 2025.11.25 F HOFFMANN LA ROCHE INC

AI summary

The application relates to (106) specific heterocyclic compounds comprising a thiazole ring, an indazol and a 6,7-dihydro-5H-pyrrolo[1,2-c]imidazole system, to pharmaceutical compositions containing them and their medical use. The compounds are described as selective allosteric inhibitors of T790M/L858R, T790M/L858R/C797S, L858R, L858R/C797S containing EGFR mutants and thus useful for the treatment of cancer, in particular non-small cell lung cancer.